Compare Manhattan Associates Inc (MANH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Zoetis Inc — how do they compare? Manhattan Associates Inc trades at $159.61 (market cap $9.79B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 3.3× Manhattan Associates Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| MANH | ZTS | |
|---|---|---|
Market Cap | $9.79B | $31.95B |
Sector | Technology | Health |
52-Week High | $227.94 | $156.76 |
52-Week Low | $120.88 | $71.91 |
Enterprise Value | $9.62B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with strong technical momentum and bullish moving averages. The company shows robust profitability with a 19.68% net income margin and has beaten EPS estimates for three consecutive quarters. However, valuation ratios like a P/E of 46.37 suggest premium pricing. Recent news highlights an ongoing legal investigation into fiduciary duties by directors, while analyst consensus remains strongly positive with a $192.80 price target.
The outlook for MANH is cautiously optimistic, driven by consistent earnings beats and solid cash flow generation. Key opportunities include sustained cloud and AI adoption, but risks involve high valuation multiples, competitive pressures, and potential legal overhangs from the Rosen Law Firm investigation. Investors should weigh strong fundamentals against elevated price levels and external uncertainties.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
